Skip to main content



Dr. Waseet Vance is board-certified in radiation oncology and practices at our Fleming Island and Southpoint locations. Originally from the Northeast, Dr. Vance received his Bachelor of Arts in Economics from Canisius College in New York, before moving to Ohio to earn his Doctor of Medicine from Northeast Ohio Medical University. He completed his internship there before heading back to New York to complete his residency at New York-Presbyterian/Columbia University Medical Center.

During his residency, in addition to specialized training in various types of radiation oncology, Dr. Vance was awarded a scholarship to receive proton therapy training at MD Anderson Cancer Center in Texas. The recipient of awards from the American Society for Radiation Oncology, American Brachytherapy Society, Radiological Society of North America, and American College of Radiation Oncology, it is no surprise that Dr. Vance was one of the youngest ever to be inducted as a Fellow of the American College of Radiation Oncology.

Dr. Vance joined CSNF in 2014 as a founding member of the radiation oncology department. His belief in custom tailoring the latest cutting-edge therapies to each individual patient has significantly improved outcomes while minimizing side effects. “I know that the diagnosis of cancer is typically the most difficult challenge a person will have to face in their life, so I strive to work closely with them, in a warm, holistic, supportive, and patient-centered environment.  He says “I believe in going above and beyond for my patients to give them the absolute best chance of success”

When not at the office, Dr. Vance enjoys sports, the great outdoors, and spending time with his son and daughter.

Curriculum Vitae


Radiation Oncology


American Brachytherapy Society
American College of Radiology
American College of Radiation Oncology
American Society of Therapeutic Radiology and Oncology
American Medical Association
Texas Medical Association
Texas Radiological Society


Northeast Ohio Medical University, Aultman Hospital


New York-Presbyterian/Columbia University Medical Center


Northeast Ohio Medical University — Canton, Ohio
Doctor of Medicine
Canisius College — Buffalo, New York
Bachelor of Arts in Economics


2012 - Present
ACRO Economics Committee
2012 - Present
Founding Member, ACRO New Practitioner Development Committee
2012 - 2013
Chairman, Covenant Health System Cancer Committee
2014 - Present
Houston Northwest Medical Center Cancer Committee
2014 - Present
Medical Director, Division of Radiation Oncology, CSNF
2016 - Present
ASTRO Code Development and Valuation Subcommittee
2012 - Present
Mentor, ACRO Resident Mentorship Program
2010 - 2011
Ex-Officio Member, ACRO National Resident Executive Committee
2009 - 2010
Columbia University ACR Task Force
2009 - Present
ASTRO Code Utilization and Application Committee
2009 - 2011
Administrator and Moderator, ACRO Residents Forum
2009 - 2010
ACRO Legislative Affairs Committee
2009 - 2010
Chief Resident, Columbia University Department of Radiation Oncology
2008 - 2010
ACRO National Resident Executive Committee
2008 - 2010
New York Presbyterian Quality Council
2003 - 2005
President, Oncology Interest Group, Northeast Ohio Medical Univ
2003 - 2005
Student Academic Mentor, Northeast Ohio Medical Univ.


2009 - 2010
Oncology Translational Research: Columbia University College of Physicians and Surgeons
2009 - 2010
Oncology Basic Science Research: Columbia University College of Physicians and Surgeons

Principal Investigator Responsibilities

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and neck. Phase N/A, Interventional
Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation . Phase N/A, Observational


“Long Term Results Including Mastectomy Rates of Accelerated Partial Breast Brachytherapy Treatment at a Single Institution.”
Radiotherapy and Oncology
“Interstitial High Dose Rate (HDR) Brachytherapy for Ductal Carcinoma In Situ of the Breast: Median 6 year Results of 66 Cases Using Multi-catheter Technique.”
“Deletion of the Betaig-h3 Gene Confers Multi-agent Chemoresistance in a Non-Small Cell Lung Cancer Cell Line.”
American Journal of Clinical Oncology
“Pathologic Analysis of CT and Ultrasound Imaging Accuracy for Prostate Radiation Therapy.”
International Journal of Radiation Oncology, Biology, Physics
“Automated and Objective Assessments of Radiation-Induced Fibrosis Using Advanced Ultrasound Imaging in Breast Cancer Radiation Therapy.”
Medical Physics
“A Comparative Analysis of In Vivo and Ex Vivo Prostate Volumes Using CT and Ultrasound imaging.”
International Journal of Radiation Oncology, Biology, Physics
“The Predictive Value of 2-year Posttreatment Biopsy after Prostate Cancer Radiotherapy for Eventual Biochemical Outcome.”
“Biochemical Disease-Free Survival Rates Following Definitive Low-Dose-Rate Prostate Brachytherapy with Dose Escalation to Biologic Target Volumes Identified with SPECT/CT Capromab Pendetide.”
International Journal of Radiation Oncology, Biology, Physics
“Phase I/II Fractionated Stereotactic Radiotherapy and Weekly Paclitaxel in Malignant Gliomas.”
International Journal of Radiation Oncology, Biology, Physics
“Assessing the Utility of a 2-year Post Treatment Biopsy for Forecasting Eventual Biochemical Failure and Survival.”
Proceedings of American Society of Clinical Oncology
“Higher Dose of Paclitaxel is Needed For Patients on Phenytoin: Pharmacokinetics Study in Patients With Malignant Gliomas.”